These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 7682382)

  • 1. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
    Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
    Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens.
    Ruebush TK2nd ; Campbell GH; Moreno A; Patarroyo ME; Collins WE
    Am J Trop Med Hyg; 1990 Oct; 43(4):355-66. PubMed ID: 2240363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
    Galindo CM; Acosta CJ; Schellenberg D; Aponte JJ; Roca A; Oettli A; Urassa H; Armstrong Schellenberg J; Kahigwa E; Ascaso C; Mshinda H; Lwilla F; Vidal J; Menendez C; Tanner M; Alonso PL
    Parasite Immunol; 2000 Sep; 22(9):437-43. PubMed ID: 10972850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum.
    Rodriguez R; Moreno A; Guzman F; Calvo M; Patarroyo ME
    Am J Trop Med Hyg; 1990 Oct; 43(4):339-54. PubMed ID: 2240362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial.
    Amador R; Moreno A; Murillo LA; Sierra O; Saavedra D; Rojas M; Mora AL; Rocha CL; Alvarado F; Falla JC
    J Infect Dis; 1992 Jul; 166(1):139-44. PubMed ID: 1607685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muramyl peptide adjuvants for Plasmodium falciparum and Plasmodium vivax circumsporozoite vaccines in rodent model systems.
    Bathurst IC; Gibson HL; Kansopon J; Hahm BK; Hollingdale MR; Barr PJ
    Biotechnol Ther; 1992; 3(1-2):15-34. PubMed ID: 1305890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela.
    Noya O; Gabaldón Berti Y; Alarcón de Noya B; Borges R; Zerpa N; Urbáez JD; Madonna A; Garrido E; Jimenéz MA; Borges RE
    J Infect Dis; 1994 Aug; 170(2):396-402. PubMed ID: 8035026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological responses of Gambian children to immunization with the malaria vaccine SPf66.
    Metzger WG; Haywood M; D'Alessandro U; Drakeley CJ; Weiss H; Bojang K; Targett GA; Greenwood BM
    Parasite Immunol; 1999 Jul; 21(7):335-40. PubMed ID: 10417667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
    Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
    Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
    Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F
    Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum.
    Enders B; Hundt E; Knapp B
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years.
    Patarroyo G; Franco L; Amador R; Murillo LA; Rocha CL; Rojas M; Patarroyo ME
    Vaccine; 1992; 10(3):175-8. PubMed ID: 1557933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Plasmodium falciparum malaria vaccine candidate which contains epitopes from the circumsporozoite protein and a blood stage antigen, 5.1.
    Caspers P; Etlinger H; Matile H; Pink JR; Stüber D; Takács B
    Mol Biochem Parasitol; 1991 Aug; 47(2):143-50. PubMed ID: 1719416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.
    Egan AF; Blackman MJ; Kaslow DC
    Infect Immun; 2000 Mar; 68(3):1418-27. PubMed ID: 10678955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
    Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.